Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bluebird Bio (BLUE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,854,844
  • Shares Outstanding, K 54,690
  • Annual Sales, $ 35,430 K
  • Annual Income, $ -335,640 K
  • 36-Month Beta 2.31
  • Price/Sales 189.55
  • Price/Cash Flow N/A
  • Price/Book 3.36

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -2.77
  • Number of Estimates 11
  • High Estimate -2.55
  • Low Estimate -2.96
  • Prior Year -2.52
  • Growth Rate Est. (year over year) -9.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
102.21 +21.92%
on 10/29/18
139.74 -10.83%
on 11/05/18
+3.91 (+3.24%)
since 10/19/18
3-Month
102.21 +21.92%
on 10/29/18
176.55 -29.42%
on 08/31/18
-33.39 (-21.13%)
since 08/17/18
52-Week
102.21 +21.92%
on 10/29/18
236.17 -47.24%
on 03/13/18
-38.59 (-23.65%)
since 11/17/17

Most Recent Stories

More News
Market Trends Toward New Normal in PlayAGS, BEST, Inc. Sponsored ADR, Verrica Pharmaceuticals, Telenav, bluebird bio, and CompX International -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of PlayAGS, Inc. (NYSE:AGS),...

VRCA : 13.50 (+0.37%)
CIX : 13.80 (+0.58%)
BLUE : 122.78 (-2.04%)
TNAV : 4.41 (-0.23%)
BSTI : 6.00 (-1.80%)
AGS : 19.70 (-4.42%)
bluebird bio to Present at the Evercore ISI HealthCONx Conference

bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the Evercore ISI HealthCONx Conference, Wednesday, November 28, at 4:15 p.m. ET at the...

BLUE : 122.78 (-2.04%)
Look for Shares of Bluebird Bio Inc to Potentially Rebound after Yesterday's 3.92% Sell Off

Bluebird Bio Inc (NASDAQ:BLUE) traded in a range yesterday that spanned from a low of $113.88 to a high of $123.80. Yesterday, the shares fell 3.9%, which took the trading range below the 3-day low of...

BLUE : 122.78 (-2.04%)
Global Cell Therapy Market Opportunities Forecast 2018-2025 with Case Studies Featuring, Novartis, Avexis, MaSTherCell, Zelluna, Celgene & Bluebird Bio

The "Growth Opportunities in the Global Cell Therapy Market, Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

BLUE : 122.78 (-2.04%)
NVS : 87.95 (+0.23%)
CELGZ : 0.88 (-4.86%)
Watch for Bluebird Bio Inc to Potentially Rebound After Falling 3.32% Yesterday

Bluebird Bio Inc (NASDAQ:BLUE) traded in a range yesterday that spanned from a low of $126.13 to a high of $131.90. Yesterday, the shares fell 3.3%, which took the trading range below the 3-day low of...

BLUE : 122.78 (-2.04%)
Regeneron (REGN) Q3 Earnings Beat Estimates, Revenues In Line

Regeneron (REGN) Q3 results beat on earnings, while sales meet expectations. However, the company's dependence on Eylea to boost revenues is a concern.

BAYRY : 17.8000 (-0.67%)
BLUE : 122.78 (-2.04%)
REGN : 340.75 (-1.33%)
SNY : 44.90 (-0.44%)
Today's Research Reports on Trending Tickers: bluebird bio and Geron

NEW YORK, NY / ACCESSWIRE / November 6, 2018 / U.S. equities closed mostly higher on Monday as investors awaited details from the Fed's two-day policy meeting and midterm congressional elections. The Dow...

BLUE : 122.78 (-2.04%)
bluebird (BLUE) Q3 Loss Narrower Than Expected, Revenues Beat

bluebird (BLUE) incurs narrower-than-expected Q3 loss on account of higher collaboration revenues. The pipeline progress looks encouraging.

CELG : 69.39 (-0.37%)
BLUE : 122.78 (-2.04%)
GILD : 68.54 (-0.95%)
REGN : 340.75 (-1.33%)
Bluebird Bio (BLUE) Reports Q3 Loss, Tops Revenue Estimates

Bluebird (BLUE) delivered earnings and revenue surprises of 5.21% and 39.36%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

BLUE : 122.78 (-2.04%)
bluebird bio Reports Third Quarter 2018 Financial Results and Highlights Operational Progress

--- Ended quarter with $2.0 billion in cash, cash equivalents and marketable securities -

BLUE : 122.78 (-2.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade BLUE with:

Business Summary

Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio,...

See More

Key Turning Points

2nd Resistance Point 130.01
1st Resistance Point 127.68
Last Price 122.78
1st Support Level 121.63
2nd Support Level 117.91

See More

52-Week High 236.17
Fibonacci 61.8% 185.00
Fibonacci 50% 169.19
Fibonacci 38.2% 153.38
Last Price 122.78
52-Week Low 102.21

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar